ArticleFrontiers in oncology2026
SF3B4 stabilizes SREBF1 via 3'UTR binding to drive hepatocellular carcinoma progression.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) represents a leading cause of cancer-associated deaths worldwide, and its development is strongly associated with aberrant RNA processing and metabolic reprogramming. Splicing factor 3B subunit 4 (SF3B4), the core component of the U2 spliceosome, has been implicated in tumorigenesis; however, its post-transcriptional functions and role in metabolic regulation in HCC remain unclear. Methods: SF3B4 expression and its prognostic significance were assessed using TCGA pan-cancer datasets and clinical HCC samples. SF3B4 was either silenced or overexpressed in HCC cell lines, followed by full-length transcriptome sequencing via Oxford Nanopore Technology to analyze global transcriptional and alternative splicing changes. SF3B4-RNA interactions were examined using RNA immunoprecipitation, dual-luciferase reporter assays, RNA pull-down, and mRNA stability assays. Functional assays assessed cell proliferation, apoptosis, invasion, and migration. Rescue experiments involved overexpressing SREBF1 in SF3B4-silenced cells. Results: SF3B4 expression was significantly elevated in HCC tissues and correlated with poor OS and DFS. Transcriptomic analyses showed that SF3B4 knockdown induced widespread transcriptional remodeling and extensive alternative splicing reprogramming. Integrative analyses identified sterol regulatory element-binding transcription factor 1 (SREBF1) as a direct downstream target of SF3B4. Mechanistically, SF3B4 bound directly to the 3' untranslated region (3'UTR) of SREBF1 mRNA, enhancing its stability and expression. Functional assays demonstrated that SREBF1 promoted HCC cell proliferation, invasion, and migration, while inhibiting apoptosis. Notably, SREBF1 overexpression partially rescued the malignant phenotypes and transcriptomic alterations induced by SF3B4 knockdown. Conclusion: This study reveals a novel post-transcriptional mechanism in which SF3B4 promotes HCC progression by stabilizing SREBF1 mRNA through direct 3'UTR binding. The SF3B4-SREBF1 axis connects RNA metabolism dysregulation to lipid metabolic reprogramming, offering new mechanistic insights and potential therapeutic targets for HCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.